Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Weapon Against Chemotherapy-Related Nausea and Vomiting in Cancer Treatment: Varubi (rolapitant)

A New Weapon Against Chemotherapy-Related Nausea and Vomiting in Cancer Treatment: Varubi (rolapitant)

When I inform patients before chemotherapy, one of their main concerns is how much nausea they will experience. A new drug, Varubi (rolapitant), was approved on 2 September by the United States Food and Drug Administration (FDA) because it successfully prevented delayed chemotherapy-related nausea and vomiting in adults.

As everyone now knows, chemotherapy is effective in many cancers and produces positive results. Drugs used to prevent cancer cell growth and multiplication and destroy these cells circulate throughout the body, creating widespread effects.

However, chemotherapy can cause side effects. Patients may experience problems affecting daily life, particularly nausea and vomiting, as well as fatigue, loss of appetite and constipation. Medicines developed through extensive research now make protection against these effects possible. The FDA recently announced one notable study in this area.

Varubi (rolapitant), combined with the anti-nausea drugs granisetron and dexamethasone, prevented delayed chemotherapy-related nausea and vomiting. It is a neurokinin-1 (NK-1) receptor antagonist. NK-1 receptors play a critical role in nausea and vomiting triggered by some chemotherapies, particularly in the delayed period (24 – 120 hours afterward). The most frequently reported side effects of Varubi were low white blood cell counts (neutropenia), hiccups, reduced attention and dizziness.

Dear friends, it appears we now have another weapon against chemotherapy-related nausea and vomiting, which can adversely affect cancer patients' lives. We will closely follow whether this drug receives approval in our country and share developments.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Weapon Against Chemotherapy-Related Nausea and Vomiting in Cancer Treatment: Varubi (rolapitant)

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy